Veracyte price target lowered to $37 from $45 at Guggenheim

Guggenheim lowered the firm’s price target on Veracyte (VCYT) to $37 from $45 and keeps a Buy rating on the shares. The firm adjusted its 2025 revenue and test volumes based on recent management commentary, updated its model for the latest 10K release post-earnings and revised its price target to reflect multiple compression in the peer group.